BRTX BIORESTORATIVE THERAPIES INC revenue, earnings and financials
For the quarter ended March 31, 2026, BIORESTORATIVE THERAPIES INC reported revenue of $23.2K (down 7.3% from a year earlier), net income of −$2.15M and diluted EPS of −$0.12; over the last four quarters revenue was $358K and net income −$11.1M; for the fiscal year ended December 2025 revenue was $360K, down 10.3% on the year before.
BRTX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $360K, gross profit $336K, operating income −$15.6M, net income −$14.2M (margin -3959.4%), EPS −$1.58
- Fiscal year ended Dec 2024: revenue $401K, gross profit $373K, operating income −$11.6M, net income −$8.98M (margin -2239.2%), EPS −$1.16
- Fiscal year ended Dec 2023: revenue $146K, gross profit $146K, operating income −$15.2M, net income −$10.4M (margin -7145.2%), EPS −$2.47
- Fiscal year ended Dec 2022: revenue $120K, gross profit n/a, operating income −$19.0M, net income −$13.2M (margin -11037.0%), EPS −$3.65
- Fiscal year ended Dec 2021: revenue $46.0K, gross profit n/a, operating income −$26.3M, net income −$44.3M (margin -96311.5%), EPS −$37.30
BRTX quarterly revenue and earnings
- Quarter ended Mar 31, 2026: revenue $23.2K (down 7.3% year over year), net income −$2.15M, EPS −$0.12
- Quarter ended Dec 31, 2025 (from the annual report): revenue $19.6K (down 54.7% year over year), net income −$3.21M, EPS −$0.31
- Quarter ended Sep 30, 2025: revenue $11.8K (down 94.9% year over year), net income −$3.04M, EPS −$0.33
- Quarter ended Jun 30, 2025: revenue $303K (up 240.4% year over year), net income −$2.66M, EPS −$0.30
- Quarter ended Mar 31, 2025: revenue $25.0K (down 28.6% year over year), net income −$5.34M, EPS −$0.64
- Quarter ended Dec 31, 2024 (from the annual report): revenue $43.3K (up 124.4% year over year), net income −$1.64M, EPS −$0.20
- Quarter ended Sep 30, 2024: revenue $234K (up 660.9% year over year), net income −$1.09M, EPS −$0.13
- Quarter ended Jun 30, 2024: revenue $89.1K (up 38.1% year over year), net income −$4.03M, EPS −$0.50
- Quarter ended Mar 31, 2024: revenue $35.0K (up 11.8% year over year), net income −$2.22M, EPS −$0.33
- Quarter ended Dec 31, 2023 (from the annual report): revenue $19.3K (up 421.6% year over year), net income −$2.30M, EPS $0.54
- Quarter ended Sep 30, 2023: revenue $30.7K (up 5.9% year over year), net income $4.77M, EPS $0.39
- Quarter ended Jun 30, 2023: revenue $64.5K (down 9.3% year over year), net income −$5.71M, EPS −$1.47
- Quarter ended Mar 31, 2023: revenue $31.3K (up 95.6% year over year), net income −$7.17M, EPS −$1.93
- Quarter ended Dec 31, 2022 (from the annual report): revenue $3.70K (down 26.0% year over year), net income −$2.67M, EPS −$0.15
- Quarter ended Sep 30, 2022: revenue $29.0K (up 262.5% year over year), net income −$5.45M, EPS −$1.50
- Quarter ended Jun 30, 2022: revenue $71.1K (up 374.0% year over year), net income $3.10M, EPS $0.33
- Quarter ended Mar 31, 2022: revenue $16.0K (down 11.1% year over year), net income −$8.21M, EPS −$2.33
- Quarter ended Dec 31, 2021 (from the annual report): revenue $5.00K, net income −$20.4M, EPS −$32.30
- Quarter ended Sep 30, 2021: revenue $8.00K, net income −$4.18M, EPS −$4.99
- Quarter ended Jun 30, 2021: revenue $15.0K, net income −$4.06M, EPS $0.00
BRTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$10.8M, share buybacks $0
- Fiscal year ended Dec 2024: operating cash flow −$8.23M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$6.43M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$5.91M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$3.33M, share buybacks n/a
BRTX balance sheet
- Mar 31, 2026: cash $3.11M, total assets $4.64M, total liabilities n/a, shareholders' equity $3.03M
- Dec 31, 2025: cash $1.51M, total assets $4.08M, total liabilities n/a, shareholders' equity $357K
- Sep 30, 2025: cash $602K, total assets $5.64M, total liabilities n/a, shareholders' equity $2.21M
- Jun 30, 2025: cash $1.56M, total assets $8.52M, total liabilities $3.67M, shareholders' equity $4.85M
- Mar 31, 2025: cash $1.23M, total assets $10.3M, total liabilities $4.18M, shareholders' equity $6.14M
- Dec 31, 2024: cash $548K, total assets $12.3M, total liabilities $3.75M, shareholders' equity $8.53M
- Sep 30, 2024: cash $1.49M, total assets $14.6M, total liabilities $4.58M, shareholders' equity $9.99M
- Jun 30, 2024: cash $2.25M, total assets $16.1M, total liabilities $5.32M, shareholders' equity $10.8M
What is BRTX's revenue?
BIORESTORATIVE THERAPIES INC reported $358K of revenue over its last four quarters, through March 31, 2026.
Is BRTX profitable?
No. BIORESTORATIVE THERAPIES INC lost $11.1M over the last four quarters.
What is BRTX's EPS?
Diluted earnings per share over the last four quarters were −$1.06; −$0.12 in the latest quarter.